Uremic Toxins and Atrial Fibrillation: Mechanisms and Therapeutic Implications

Area of Science:

• Cardiology
• Nephrology
• Biochemistry

Background:

• Atrial fibrillation (AF) is a common heart arrhythmia.
• Chronic kidney disease (CKD) is strongly associated with AF.
• Uremic toxins, particularly indoxyl sulfate (IS), are implicated in AF development.

Purpose of the Study:

• To review the mechanisms by which uremic toxins promote AF.
• To summarize clinical studies on uremic toxin-induced AF.
• To explore the role of IS in AF pathogenesis and recurrence.

Main Methods:

• Review of animal studies on IS and AF.
• Analysis of clinical data linking serum IS levels to AF recurrence after ablation.
• Discussion of potential therapeutic strategies targeting uremic toxins.

Main Results:

• Animal studies demonstrate IS promotes myocardial fibrosis, inflammation, and oxidative stress, exacerbating AF.
• AST-120, a uremic toxin absorbent, reduced AF in rodent models.
• Elevated serum IS levels predict higher AF recurrence rates post-catheter ablation in patients.

Conclusions:

• Uremic toxins, especially IS, play a significant role in AF development and progression.
• Serum IS is a predictor of AF recurrence after catheter ablation.
• Targeting uremic toxins may offer a novel therapeutic approach for AF management in CKD patients.